Kooriyama Shiyun'ichi
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position Assistant Professor |
|
Language | English |
Title | Role of photodynamic therapy using talaporfin sodium and a semiconductor laser in patients with newly diagnosed glioblastoma |
Conference | The 34th Japan Neurosurgery English Forum |
Conference Type | Nationwide Conferences |
Presentation Type | Speech |
Lecture Type | General |
Publisher and common publisher | ◎FUKUI Atsushi, NITTA Masayuki, MURAGAKI Yoshihiro, MARUYAMA Takashi, ISEKI Hiroshi, KOMORI Takashi, IKUTA Soko, SAITO Taiichi, YASUDA Takayuki, HOSONO Junji , OKAMOTO Saori, KORIYAMA Shunichi, KAWAMATA Takakazu |
Date | 2019/07/26 |
Venue (city and name of the country) |
Kawasaki, Japan |
Society abstract | The 34th Japan Neurosurgery English Forum JNEF2019 Program&Abstract 22 |
Summary | Objective: In this study on the effectiveness and safety of photodynamic therapy (PDT) using
talaporfin sodium, the long-term follow-up results of 30 patients with newly diagnosed glioblastoma enrolled from 2009 to 2016 were analyzed and compared with those of 164 patients treated without PDT during the same period. Methods: The main outcome measures were the median overall survival (OS) and progression-free survival (PFS) times. Moreover, the adverse events and radiological changes after PDT, as well as the patterns of recurrence, were compared between the groups. Univariate and multivariate analyses were performed to identify the prognostic factors, including PDT, among patients with newly diagnosed glioblastoma. Results: The median PFS times of the PDT and control groups were 19.6 and 9.0 months respectively (p = 0.016). The median OS times were 27.4 and 22.1 months respectively (p = 0.0327). Multivariate analyses found PDT, preoperative Karnofsky Performance Scale score, and IDH mutation to be significant independent prognostic factors for both OS and PFS. Eighteen of 30 patients in the PDT group experienced tumor recurrence, including local recurrence, distant recurrence, and dissemination in 10, 3, and 4 patients, respectively. Conversely, 141 of 164 patients in the control group experienced tumor recurrence, including 101 cases of local recurrence. The rate of local recurrence tended to be lower in the PDT group (p = 0.06). Conclusions: The results of the present study suggest that PDT with talaporfin sodium provides excellent local control, with few adverse effects even in cases of multiple laser irradiations, as well as potential survival benefits for patients with newly diagnosed glioblastoma. |